BioSig Technologies, Inc. (BSGM) | Investment Case

1. Company Snapshot

1.a. Company Description

BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company.The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time.It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures.

The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems.BioSig Technologies, Inc.was incorporated in 2009 and is headquartered in Westport, Connecticut.

Show Full description

1.b. Last Insights on BSGM

BioSig Technologies' recent performance was driven by a Zacks Rank upgrade to #2 (Buy), indicating growing optimism about its earnings prospects. This upgrade is a positive indicator of the company's potential for future growth. Additionally, BioSig has confirmed full compliance with Nasdaq requirements, ensuring its continued listing on the Nasdaq Capital Market. This development demonstrates the company's ability to meet regulatory standards, further enhancing investor confidence.

1.c. Company Highlights

Last Price	6.1
Change Percentage	37.08%
Open	4.44
Previous Close	4.45
Market Cap ( Millions)	191
Volume	3012946
Year High	14.11
Year Low	0.23
M A 50	4.94
M A 200	3.03

FCF Yield	-4.13%
Dividend Yield	0.00%
ROE	1759.74%
Debt / Equity	0.00%
Net Debt / EBIDTA	27.78%
Price To Book	-298.27
Price Earnings Ratio	-51.03
Price To FCF	-24.22
Price To sales	14702.56
EV / EBITDA	-4.53

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Streamex Corp., NASDAQ: STEX & Simplify Asset Management $10 billion USD AUM ETF Manager Announces Letter of Intent Pursuing a Strategic Partnership to Drive ETF Innovation through Integration of Tokenized Gold Yield Assets and Tokenization of Existing ETFs

Sep -17

Source: globenewswire.com

BioSig Technologies, Inc. Announces Corporate Rebrand to Streamex Corp.

Sep -10

Source: globenewswire.com

BioSig Technologies Supplements Clarification on Recent Schedule 14A Filing. Closing of Merger with Streamex Exchange Corporation Not Affected

Sep -03

Source: globenewswire.com

Streamex (BSGM) to Participate in the 5th Annual Needham Virtual Crypto 1x1 Conference on September 4th

Aug -28

Source: globenewswire.com

BioSig Technologies, Inc. & Streamex Announce Closing of $15 Million Public Offering

Aug -15

Source: globenewswire.com

BioSig Technologies Inc. Announces Pricing of $15 Million Public Offering

Aug -14

Source: globenewswire.com

BioSig Technologies Inc. Announces Proposed Public Offering

Aug -13

Source: globenewswire.com

Here's 1 New Billion-Dollar Reason to Buy Solana And Never Look Back

Jul -28

Source: fool.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (0.00%)

6. Segments

BioSig

Expected Growth: 14.1%

Growing demand for non-invasive cardiovascular health monitoring, increasing prevalence of cardiovascular diseases, and advancements in wearable technology drive the growth of BioSig's wearable device market.

7. Detailed Products

PURE EP

A software platform designed to improve signal fidelity and analytics for electrophysiology procedures.

PURE EP Navigator

A 3D mapping and navigation system for cardiac ablation procedures.

BioSig IDI

A novel signal processing technology for intracardiac signals.

BioSig RHYTHM

A software platform for cardiac rhythm analysis and visualization.

8. BioSig Technologies, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

BioSig Technologies, Inc. operates in the medical technology industry, which has a moderate threat of substitutes. While there are alternative treatments and devices available, BioSig's proprietary technology and innovative approach to cardiac signal processing provide a competitive advantage.

Bargaining Power Of Customers

BioSig Technologies, Inc. has a diverse customer base, including hospitals, clinics, and medical research institutions. However, the company's products are highly specialized, and customers have limited bargaining power due to the unique nature of BioSig's technology.

Bargaining Power Of Suppliers

BioSig Technologies, Inc. relies on a limited number of suppliers for its components and materials. While the company has established relationships with its suppliers, it is still vulnerable to supply chain disruptions and price fluctuations.

Threat Of New Entrants

The medical technology industry is highly competitive, and new entrants can easily disrupt the market with innovative products and services. BioSig Technologies, Inc. must continue to innovate and invest in research and development to stay ahead of potential competitors.

Intensity Of Rivalry

The medical technology industry is highly competitive, with numerous established players and new entrants vying for market share. BioSig Technologies, Inc. must differentiate itself through its proprietary technology and strategic partnerships to maintain its competitive edge.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	-18.37%
Debt Cost	3.95%
Equity Weight	118.37%
Equity Cost	7.44%
WACC	8.09%
Leverage	-15.52%

11. Quality Control: BioSig Technologies, Inc. passed 5 out of 9 key points

Strong Liquidity

Low Debt

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

BioSig Technologies

A-Score: 4.9/10

Value: 8.0

Growth: 6.9

Quality: 4.8

Yield: 0.0

Momentum: 10.0

Volatility: 0.0

1-Year Total Return ->

Nevro

A-Score: 4.7/10

Value: 9.2

Growth: 4.7

Quality: 4.3

Yield: 0.0

Momentum: 7.5

Volatility: 2.3

1-Year Total Return ->

Butterfly Network

A-Score: 3.8/10

Value: 7.0

Growth: 4.6

Quality: 4.0

Yield: 0.0

Momentum: 6.0

Volatility: 1.0

1-Year Total Return ->

NeuroOne Medical Technologies

A-Score: 3.7/10

Value: 6.8

Growth: 6.1

Quality: 4.2

Yield: 0.0

Momentum: 4.0

Volatility: 1.3

1-Year Total Return ->

Accelerate Diagnostics

A-Score: 3.5/10

Value: 10.0

Growth: 5.6

Quality: 5.0

Yield: 0.0

Momentum: 0.0

Volatility: 0.3

1-Year Total Return ->

Cytek Biosciences

A-Score: 3.4/10

Value: 6.3

Growth: 7.0

Quality: 3.8

Yield: 0.0

Momentum: 1.5

Volatility: 2.0

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

33.44%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

8.09%

BioSig Technologies, Inc. - US09073N3008

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on BSGM

1.c. Company Highlights

Weak Momentum

Medium Volatility

Fairly Valued

Earnings Beats

More Volatile

Earnings Miss

Average Quality

Stable Momentum

Strong Momentum

Cheaper

Lower Quality

Average Growth

2. Transcript Summary

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (0.00%)

6. Segments

BioSig

Expected Growth: 14.1%

7. Detailed Products

PURE EP

PURE EP Navigator

BioSig IDI

BioSig RHYTHM

8. BioSig Technologies, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: BioSig Technologies, Inc. passed 5 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

6.1$

Current Price

6.1$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA